Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8010 | 0.78 | BBOX1 (0.41) | SLC22A16MAPTBBOX1TSHRCHRM2 | |
| SCHEMBL14742785 | 0.78 | BBOX1 (0.41) | SLC22A16MAPTBBOX1TSHRCHRM2 | |
| Bromide SCHEMBL8416789 | 0.76 | BBOX1 (0.39) | SLC22A16MAPTBBOX1TSHRCHRM2 | |
| Hydrochloric Acid SCHEMBL434365 | 0.76 | MAPT (0.43) | SLC22A16MAPTBBOX1TSHRCHRM2 | |
| Water SCHEMBL17373732 | 0.76 | BBOX1 (0.39) | SLC22A16MAPTBBOX1TSHRCHRM2 | |
| SCHEMBL14739985 | 0.76 | MAPT (0.34) | SLC22A16MAPTTSHRCHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL933391 | 0.74 | MAPT (0.41) | SLC22A16MAPTBBOX1TSHRCHRM2 | |
| Hydroxyamine SCHEMBL8584616 | 0.74 | BBOX1 (0.43) | SLC22A16MAPTBBOX1TSHRCHRM2 | |
| Hydrochloric Acid SCHEMBL2355625 | 0.74 | MAPT (0.41) | SLC22A16MAPTBBOX1TSHRCHRM2 | |
| Hexane SCHEMBL3645235 | 0.74 | FDPS (0.47) | BBOX1LAP3FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371211-B2 | Packaging solutions | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-07-29 | — | — | US | disclosed |
| US-20250154289-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2025-05-15 | — | — | US | disclosed |
| US-12227598-B2 | Glycophospholipid polymeric network and use thereof | BAUSCH & LOMB INCORPORATED (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250040673-A1 | PACKAGING SOLUTIONS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2025-02-06 | — | — | US | disclosed |
| US-20240270419-A1 | PACKAGING SOLUTIONS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-08-15 | — | — | US | disclosed |
| US-12012238-B2 | Packaging solutions | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| EP-4346922-A2 | PACKAGING SOLUTIONS | Bausch + Lomb Ireland Limited (IE) | 2024-04-10 | — | — | EP | disclosed |
| US-20230257485-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2023-08-17 | — | — | US | disclosed |
| US-11673974-B2 | Glycophospholipid polymeric network and use thereof | BAUSCH & LOMB INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220411115-A1 | PACKAGING SOLUTIONS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2022-12-29 | — | — | US | disclosed |
| WO-2022248127-A2 | PACKAGING SOLUTIONS | BAUSCH + LOMB IRELAND LIMITED (IE) | 2022-12-01 | — | — | WO | disclosed |
| EP-3962961-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | Bausch & Lomb Incorporated (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114096567-A | Glycophospholipid polymer networks and uses thereof | 鲍希与洛姆伯股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2020222914-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200339710-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | BAUSCH HEALTH US, LLC | 2020-10-29 | — | — | US | disclosed |
| EP-2751123-B1 | BIOCOMPATIBLE MATERIAL | VERTELLUS HOLDINGS LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9006305-B2 | Biocompatible material | VERTELLUS SPECIALTIES INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2751123-A1 | BIOCOMPATIBLE MATERIAL | Vertellus Specialties Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033554-A1 | BIOCOMPATIBLE MATERIAL | VERTELLUS SPECIALTIES INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059970-A1 | BIOCOMPATIBLE MATERIAL | VERTELLUS HOLDINGS, LLC | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154289-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | ALG1, CSGALNACT1, FUT6 | SLC22A16 1533/4885MAPT 3756/4885BBOX1 3421/4885 |
| US-11673974-B2 | Glycophospholipid polymeric network and use thereof | ALG1, CSGALNACT1, FUT5 | SLC22A16 2752/4885MAPT 4184/4885BBOX1 2833/4885 |
| US-20200339710-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | ALG1, CSGALNACT1, FUT5 | SLC22A16 2752/4885MAPT 4184/4885BBOX1 2833/4885 |
| US-20130059970-A1 | BIOCOMPATIBLE MATERIAL | VCL, ITGAM, MACF1 | SLC22A16 757/4885MAPT 1791/4885BBOX1 1234/4885 |
| US-20230257485-A1 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | ALG1, CSGALNACT1, FUT6 | SLC22A16 1533/4885MAPT 3756/4885BBOX1 3421/4885 |
| US-12227598-B2 | Glycophospholipid polymeric network and use thereof | ALG1, CSGALNACT1, FUT6 | SLC22A16 1533/4885MAPT 3756/4885BBOX1 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.